DrugPatentWatch Database Preview

Details for Patent: RE44874

Which drugs does patent RE44874 protect, and when does it expire?

Patent RE44874 protects ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.

This patent has forty-six patent family members in thirty countries.

Summary for Patent: RE44874

Title:	Phenethanolamine derivatives for treatment of respiratory diseases
Abstract:	The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases ##STR00001##
Inventor(s):	Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	13/719,797
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation; Use; Process; Device; Delivery;

Drugs Protected by US Patent RE44874

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.	➤ Sign Up
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER	➤ Sign Up
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS	➤ Sign Up
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Foreign Priority and PCT Information for Patent: RE44874

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0122201.7	Sep 14, 2001
United Kingdom	0126997.6	Nov 9, 2001

PCT Information
PCT Filed	September 11, 2002	PCT Application Number:	PCT/GB02/04140
PCT Publication Date:	March 27, 2003	PCT Publication Number:	WO03/024439

Non-Orange Book US Patents Family Members for Patent RE44874

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,776,895	Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases	➤ Sign Up
7,361,787	Phenethanolamine derivatives for treatment of respiratory diseases	➤ Sign Up
8,198,483	Phenethanolamine derivatives for treatment of respiratory diseases	➤ Sign Up
7,982,067	Phenethanolamine derivatives for treatment of respiratory diseases	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent RE44874

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Taiwan	I299661	➤ Sign Up
Slovenia	2042168	➤ Sign Up
Slovenia	1425001	➤ Sign Up
Russian Federation	2007124187	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: RE44874

Foreign Priority and PCT Information for Patent: RE44874

For more information try a trial or see the plans and pricing